GI Cancer Protocols

Metastatic Heptocellular (CALGB 80802): Phase III Randomized Study of Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Metastatic Colorectal (CALGB 80405): A Phase III Trial of Irinotecan/5-FU/LV (FOLFIRI) or Oxal/5-FU/LV (FOLFOX) with Bevacizumab or Cetuximab, or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Colorectal Cancer (RWH 298-04): Phase Ia/Ib Trial of 2nd Generation Designer T Cells in Colorectal Carcinoma
Pancreatic Cancer (NLG-0405): A Phase lll Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute Pancreatic Cancer Vaccine in Subjects with Surgically Resected Pancreatic Cancer
Stage III Colon Cancer (CALGB 80702): A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Sarcoma (IPM3001): A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma

Frances D’Allesandro, C.C.R.P.
Clinical Research Coordinator, RWMC Protocol Office
Phone: (401) 456-2698 - Fax: (401) 456-2658 - fdallesandro@chartercare.org
Jessica Donaghy A.S.
Administrative Associate, RWMC Protocol Office
Phone: (401) 456-5393 - Fax: (401) 456-2658 - jdonaghy@chartercare.org

Roger Williams Medical Center